Results 151 to 160 of about 2,870,340 (221)

Effects of a non-xanthine adenosine antagonist. CGS 15943, and a phosphodiesterase inhibitor, Ro 20-1724, in a light/dark test in mice

, 1995
Masahiro Imaizumt, Shuichi Miyazaki, Haruhiko Machida, Kenji Onodera   +3 more
openalex   +1 more source

Phosphodiesterase 4 inhibitors and db‐cAMP inhibit TNF‐α release from human mononuclear cells. Effects of cAMP and cGMP‐dependent protein kinase inhibitors [PDF]

, 1996
Aziz Hichami, Elisabeth Boichot, Nicolas Germain, E.V. Berdyshev, Olivier Coqueret, Vincent Lagente   +5 more
openalex   +1 more source

Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich's Ataxia Mouse Model. [PDF]

Neurotherapeutics, 2019
Mollá B, Muñoz-Lasso DC, Calap P, Fernandez-Vilata A, de la Iglesia-Vaya M, Pallardó FV, Moltó MD, Palau F, Gonzalez-Cabo P.   +8 more
europepmc   +1 more source

E4021, A Novel cGMP Phosphodiesterase (PDE5) Inhibitor, Improves Pulmonary Hemodynamics in Newborn Lambs with PPHN † 1645 [PDF]

, 1998
Robert C Dukarm, James A. Russell, Sylvia F. Gugino, Frederick C. Morin, Robin H. Steinhorn   +4 more
openalex   +1 more source

Rolipram, a Phosphodiesterase-4-Selective Inhibitor, Promotes the Survival of Cultured Rat Dopaminergic Neurons.

, 1997
Nobuyuki Yamashita, Akiko Hayashi, Jun Baba, Aiko Sawa   +3 more
openalex   +1 more source

Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Current pharmaceutical design, 2014
David J Titus, A. Oliva, N. Wilson, C. Atkins   +3 more
semanticscholar   +1 more source

Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease. [PDF]

Front Aging Neurosci, 2019
Cuadrado-Tejedor M, Pérez-González M, García-Muñoz C, Muruzabal D, García-Barroso C, Rabal O, Segura V, Sánchez-Arias JA, Oyarzabal J, Garcia-Osta A.   +9 more
europepmc   +1 more source

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. [PDF]

Cochrane Database Syst Rev, 2018
Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, Lyon JA, Singh SK, Mandal AK.   +8 more
europepmc   +1 more source

Fetal sex and the relative reactivity of human umbilical vein and arteries are key determinants in potential beneficial effects of phosphodiesterase inhibitors.

J Appl Physiol (1985)
Peyter AC, Beaumann M, Delhaes F, Joye S, Menétrey S, Baud D, Tolsa JF.   +6 more
europepmc   +1 more source

cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases

Expert Opinion on Therapeutic Patents, 2014
Ana Martínez, C. Gil
semanticscholar   +1 more source